Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

Medicine (United States)

Volumn 94, Issue 44, 2015, Pages e1674-

  Gu, Hai Feng ^a   Gu, Ling Jia ^b   Wu, Yue ^a   Zhao, Xiao Hong ^a   Zhang, Qing ^a   Xu, Zhe Rong ^a   Yang, Yun Mei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAIZHOU FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; DENOSUMAB; PLACEBO; PROCOLLAGEN TYPE I AMINOTERMINAL PROPEPTIDE; TELOPEPTIDE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; BONE TURNOVER; CROSS LINKING; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; FEMALE; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84958267908     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001674     Document Type: Article

References (24)

1. NIH. Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285:785-795.
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
3. Prevention and management of osteoporosis: WHO technical report series 921 Geneva: World Health Organization; 2003:1-164.
4. Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013;4:147-152.
5. Fazil M, Baboota S, Sahni JK, et al. Bisphosphonates: therapeutics potential and recent advances in drug delivery. Drug Deliv. 2015;22:1-9.
6. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23:317-326.
7. McClung MR, Boonen S, Törring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27:211-218.
8. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599-2607.
9. Nakamura T, Matsumoto T, Sugimoto T, et al. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23:1131-1140.
10. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972-980.
11. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22:1832-1841.
12. Pitale S, Thomas M, Rathi G, et al. A randomized placebocontrolled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian J Endocrinol Metab. 2015;19:148-154.
13. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059-1066.
14. von Keyserlingk C, Hopkins R, Anastasilakis A, et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum. 2011;41:178-186.
15. Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68:1409-1418.
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
17. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Updated March 2011.
18. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574-1577.
19. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
20. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149-2157.
21. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483-4492.
22. Poole KE, Treece GM, Gee AH, et al. Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res. 2015;30:46-54.
23. Lin T, Wang C, Cai XZ, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012;66:399-408.
24. Migliore A, Broccoli S, Massafra U, et al. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci. 2013;17:658-667.